J96.0
Conditions
Interventions
Group 1: The pharmacokinetics of different antiinfective drugs (see primary endpoint) will be analysed systematically in adult patients treated with ECMO.
Serum samples will be drawn on three days wi
Sponsors
Universitätsklinikum Hamburg-EppendorfKlinik für Intensivmedizin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Consecutive inclusion of adult patients (Age = 18 years) of both genders, who need an ECMO and receive at least one of the following antiinfective drugs: anidulafungin, ceftazidime, ciprofloxacin, clarithromycin, colistin, linezolid, meropenem, piperacillin/tazobactam, posaconazole, tigecyclin, vancomycin or voriconazole.
Exclusion criteria
Exclusion criteria: Age < 18 years missing informed content
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the study is the systematic evaluation of serum levels of different antiinfectives in critically ill patients undergoing ECMO treatment. The main Focus is to Analyse, whether this special patient population is treated appropriately and whether the standard doses of antiinfectives are adequate and can be maintained. | — |
Secondary
| Measure | Time frame |
|---|---|
| - 28-days mortality, if the patient is treated as an inpatient in the UKE at that timepoint - length of stay in the intensive care unit and in the hospital - Progression parameter of infection markers (leucocytes, CRP, PCT) - infections, that might be present due to potential underdosing of antiinfectives | — |
Countries
Germany
Contacts
Public ContactDzenefa;Barbara Alihodzic;Sensen
Universitätsklinikum Hamburg-EppendorfKlinikapotheke;Universitätsklinikum Hamburg-EppendorfKlinik für Intensivmedizin
Outcome results
None listed